Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

B-I's COMBIVENT RECOMMENDED FOR COPD PATIENTS WITH CONTINUED BRONCHOSPASM

Executive Summary

B-I's COMBIVENT RECOMMENDED FOR COPD PATIENTS WITH CONTINUED BRONCHOSPASM who are on single-agent therapy by FDA's Pulmonary- Allergy Drugs Advisory Committee July 14. Boehringer Ingelheim's Combivent (ipratropium 21 mcg/albuterol 120 mcg) should be indicated for use in patients with chronic obstructive pulmonary disease "on an aerosol bronchodilator who continue to have evidence of bronchospasm and who are felt to require a second aerosol bronchodilator," the committee said. The panel voted 9-0 to recommend approval of the fixed-combination metered-dose inhaler.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS024772

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel